Evotec AG
Schnackenburgalle 114
Hamburg
22525
Germany
Tel: 49-40-560810
Fax: 49-40-56081222
Website: http://www.evotec.de/
Email: info@evotecoai.com
573 articles about Evotec AG
-
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
11/7/2023
Evotec SE and Dewpoint Therapeutics announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programs of condensate modifying therapeutics to Investigational New Drug Applications using Evotec’s industry-leading fully integrated data-driven platform.
-
IAMA Therapeutics Announces Multi-Phase, Strategic Provider Agreement with Evotec
10/2/2023
IAMA Therapeutics today announced that it has signed a multi-phase agreement with Evotec, which offers integrated drug development solutions.
-
Bristol Myers Squibb is paying a total of $95 million to the two companies for exclusive global rights to programs developed within long-term partnerships designed to further BMS’ neuro pipeline.
-
Evotec SE Annual General Meeting 2023 Approves All Proposed Agenda Items
6/20/2023
Evotec SE announced that its shareholders approved all proposals the Company's Management put to vote at the Company's virtual Annual General Meeting 2023 with the required majority.
-
Bristol Myers Squibb is expanding its strategic collaboration with German partner Evotec for eight more years to discover and develop treatments for neurodegenerative diseases.
-
Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
2/7/2023
Evotec SE announced that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effective 01 April 2023.
-
Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies
1/26/2023
Evotec SE announced that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
12/16/2022
Evotec SE announced that the Company has achieved further significant progress within its neuroscience collaboration with Bristol Myers Squibb.
-
Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Academic Institutions
10/28/2022
Evotec SE announced the launch of "Extend", a translational BRIDGE partnership in cooperation with CDP Venture Capital Sgr, a strategic pillar to Italy's economic growth and innovation, and Angelini Ventures, the Corporate Venture Capital arm of the multi-business industrial group Angelini Industries.
-
Evotec launches PanOmics Data Analysis Platform PanHunter at Bio-IT World
10/18/2022
Evotec SE announced the launch of the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World.
-
Evotec Initiates Ground-Breaking for New Biologics Facility J.POD(R) Toulouse, France (EU)
9/16/2022
Evotec SE officially launched the construction of its J.POD ® biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France.
-
Boehringer, Evotec and bioMérieux found Aurobac to combat antimicrobial resistance, Turnstone and Moffitt Expand TIL Collab, Skyhawk to gain potential $2B from Sanofi RNA splicing deal.
-
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
7/6/2022
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.
-
Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance
7/6/2022
Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.
-
Evotec Completes Acquisition of Rigenerand
7/5/2022
Evotec SE announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed.
-
Evotec SE has inked a deal with Janssen Pharmaceutical hat showcases its end-to-end integrated drug discovery and development platform.
-
Evotec Enters a Drug Discovery Collaboration with Janssen
6/14/2022
Evotec SE announced that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Sernova shared positive Phase I/II data from an ongoing clinical study of its implantable Cell Pouch device that showed evidence of in vivo active insulin production.
-
Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand
5/30/2022
Evotec SE announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for a purchase price of € 23 m.
-
Germany-based Evotec AG forged its third partnership in May, a deal with Spain’s Almirall S.A. to develop new therapeutics for severe diseases of the skin.